Loading...
•
Mar 31, 2022
Relmada Q1 2022 Earnings Report
Reported first quarter 2022 financial results and provided a corporate update.
Key Takeaways
Relmada Therapeutics reported its first quarter 2022 financial results, highlighting the progress of its REL-1017 clinical data readouts for the Reliance Phase 3 program.
The Reliance Phase 3 program for REL-1017 is progressing as planned.
Clinical data readouts for REL-1017 are expected to begin mid-year.
Enrollment of Reliance III, the monotherapy registrational Phase 3 trial, is expected to be completed and top-line results presented by mid-year 2022.
Top-line results from Reliance I and Reliance II, the adjunctive MDD studies, are expected throughout the second half of the year.
Forward Guidance
Relmada anticipates completing the enrollment of Reliance III and presenting top-line results by mid-year 2022, followed by top-line results from Reliance I and Reliance II throughout the second half of the year.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...